Big biotech, Biotech, Partnering

Elan big biotech deals Speranza Therapeutics for ELND005 license

Posted on 21 May 2013

Tags: , , ,

Elan has entered biotech deals and decides to divest ELND005 to, Speranza Therapeutics, focused on progressing the development of ELND005 (Scyllo-inositol).

Leading to the biotech deals, current indications and activity for ELND005: Bi-Polar, Agitation/Aggression in Alzheimer’s disease, and Down Syndrome.

Business objective: file in lead indication – Agitation/Aggression in Alzheimer’s disease.

Third party equity financial partner will continue with clinical plans with current management in the biotech deals.

Elan will commit $70 million to the new entity upfront as part of the biotech deals (plus up to a potential future $8 million) for an 18% minority equity position, royalties in major markets along with additional milestones, and retention of commercial rights in certain territories and markets.

The third party equity financial partner will commit $20 million for 62% equity position (plus up to a potential future $2 million).

The remaining 20% equity will be allocated among Speranza management.

This allows Elan to eliminate the operating activities associated with the development of the drug (2013 estimated spend:~ $80 million), while at the same time maintaining a share of the potential upside.

Daily news stories                                                                           

For further deal information visit Current Agreements (subscription required)


Read: more on Elan company profile, recent partnering, M&A and financing news and articles

View:Current Partnering’s Partnering Scorecard – view top life science partnering deals by value

View: Current Partnering’s Deal Metrics – the latest deal trend infographics for life science deal making

View:Current Partnering’s Big Pharma Deal Making Scorecard – latest trends in big pharma deal making activity

View: Current Partnering’s Big Biotech Deal Making Scorecard – latest trends in big biotech deal making activity

Signup: Current Partnering Dealmakers Update – weekly newsletter providing the latest life science industry deal news, deal making trends, partnering events – sign up now

Signup: Current Agreements Deals Review – monthly newsletter – reviewing the previous month’s life science deal making – partnering, M&A and financing – sign up now

Subscribe: Current Agreements life sciences partnering, M&A and financing deals database – find out more

Follow us on: LinkedIn Current Partnering | LinkedIn Business Development Network | @Currentpartner on Twitter

Print Friendly, PDF & Email

Leave a Reply